Cipla’s September-quarter outlook points to stronger Indian sales but weaker U.S. revenue, with brokerage estimates indicating how the regional split may shape the drugmaker’s consolidated earnings.
Informist’s Oct. 14 survey of nine brokerages put average consolidated net profit at INR 9.80 billion, down 28% from a year earlier, and revenue at INR 76.81 billion, up 1%. Separately, NDTV Profit reported Oct. 26 that an estimate it cited put profit at INR 9.57 billion, down 29%, and revenue at INR 76.42 billion, up 0.6%.
The estimates compiled by Informist ranged from INR 8.69 billion to INR 10.31 billion for net profit and from INR 74.17 billion to INR 80.25 billion for revenue. Seven brokerages estimated average earnings before interest, taxes, depreciation and amortization (EBITDA) of INR 14.06 billion, while reported margin estimates ranged from 17.4% to 19.2%.
For the U.S. market, the surveyed brokerages expected sales of US$170 million to US$181 million, a year-over-year decline of 22% to 27%. Their India growth estimates were 13% to 15%. NDTV Profit reported a separate range of 22% to 29% for the expected U.S. decline and 13% to 14% for India growth.
Informist reported that brokerages pointed to lower or absent sales of generic Revlimid and Lanreotide, a high comparison base, higher raw-material costs, product mix and biosimilar investment as earnings pressures. These are analysts’ explanations ahead of the results, not reported September-quarter results.
The regional forecasts follow a similar pattern in Cipla’s latest reported quarter. For the quarter ended June 30, India revenue rose 12% year over year to INR 34.52 billion, while North America revenue fell 21% to INR 15.32 billion, the company reported.
Cipla said in July that its fiscal 2027 EBITDA-margin guidance of 18.5% to 20% was broadly unchanged. The board is scheduled to consider and approve the unaudited standalone and consolidated results for the quarter and half year ended Sept. 30, Cipla said in a filing to the National Stock Exchange of India. The meeting is set for Tuesday, Oct. 27.
